- Home
- FSLR vs BGNE Comparison
FSLR vs BGNE Comparison
Compare FSLR & BGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSLR
- BGNE
- Stock Information
- Founded
- FSLR 1999
- BGNE 2010
- Country
- FSLR United States
- BGNE Cayman Islands
- Employees
- FSLR N/A
- BGNE N/A
- Industry
- FSLR Semiconductors
- BGNE Biotechnology: Pharmaceutical Preparations
- Sector
- FSLR Technology
- BGNE Health Care
- Exchange
- FSLR Nasdaq
- BGNE Nasdaq
- Market Cap
- FSLR 21.3B
- BGNE 19.2B
- IPO Year
- FSLR 2006
- BGNE 2016
- Fundamental
- Price
- FSLR $189.80
- BGNE $176.51
- Analyst Decision
- FSLR Strong Buy
- BGNE Buy
- Analyst Count
- FSLR 25
- BGNE 8
- Target Price
- FSLR $280.74
- BGNE $253.69
- AVG Volume (30 Days)
- FSLR 2.1M
- BGNE 467.6K
- Earning Date
- FSLR 10-29-2024
- BGNE 11-12-2024
- Dividend Yield
- FSLR N/A
- BGNE N/A
- EPS Growth
- FSLR 162.15
- BGNE N/A
- EPS
- FSLR 11.61
- BGNE N/A
- Revenue
- FSLR $3,850,811,000.00
- BGNE $3,351,304,621.00
- Revenue This Year
- FSLR $29.09
- BGNE $969.39
- Revenue Next Year
- FSLR $32.05
- BGNE $24.79
- P/E Ratio
- FSLR $16.41
- BGNE N/A
- Revenue Growth
- FSLR 21.77
- BGNE 50.22
- 52 Week Low
- FSLR $135.88
- BGNE $126.97
- 52 Week High
- FSLR $306.77
- BGNE $248.16
- Technical
- Relative Strength Index (RSI)
- FSLR 44.19
- BGNE 36.40
- Support Level
- FSLR $187.75
- BGNE $174.50
- Resistance Level
- FSLR $201.72
- BGNE $180.00
- Average True Range (ATR)
- FSLR 7.98
- BGNE 7.12
- MACD
- FSLR -0.60
- BGNE -2.17
- Stochastic Oscillator
- FSLR 9.51
- BGNE 10.80
About FSLR First Solar Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.
About BGNE BeiGene Ltd.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.